 OncLive | Concomitant Corticosteroid Use Compromises Efficacy of Enzalutamide in mCPRC OncLive Use of corticosteroids had a negative impact on outcomes with enzalutamide treatment as well as placebo treatment in men with metastatic castrate resistant prostate cancer (mCRPC), according to a post-hoc analysis of the Phase III AFFIRM trial reported ... Prostate Cancer Drug Winners and Losers at ASCO GU |
